导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.78% | 2746/4773 |
| 近一周 | -1.41% | 436/5462 |
| 近一月 | 0.07% | 669/5421 |
| 近一季 | -0.40% | 826/5209 |
| 近半年 | -5.81% | 2957/4920 |
| 近一年 | -1.98% | 2955/4366 |
| 近两年 | 23.21% | 2564/2954 |
| 近三年 | 13.21% | 1675/2253 |
| 成立以来 | 114.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.16% 1034/4961 |
-10.98% 4216/5312 |
- - |
- - |
| 2025 | 2.55% 3178/4813 |
-2.73% 2969/3635 |
2.06% 1911/4076 |
1.99% 3847/4524 |
1.28% 1439/4813 |
| 2024 | 17.12% 726/3463 |
3.42% 574/2808 |
0.45% 605/3014 |
11.42% 2522/3129 |
1.18% 1110/3463 |
| 2023 | 12.62% 58/2656 |
8.95% 434/2280 |
3.34% 99/2385 |
3.55% 182/2515 |
-3.41% 679/2655 |
| 2022 | 0.80% 34/2207 |
4.29% 39/1919 |
-2.31% 1773/2016 |
-5.36% 72/2113 |
4.55% 537/2208 |
| 2021 | 26.22% 100/1822 |
9.34% 55/1255 |
4.07% 926/1330 |
7.06% 197/1466 |
3.60% 415/1822 |
| 2020 | - - |
- - |
- - |
14.14% 298/1164 |
4.37% 845/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 景顺长城红利低波动100ETF VS. 长安沪深300非周期A(740101) |